New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GDOT;ELN;MRK;CTRP;DELL;NFLX;MAT;MCK;VVUS;ALKS;ADNC;LTM;TSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 25, 2015
05:57 EDTALKSUBS says remain on sidelines with respect to Alkermes
Subscribe for More Information
February 24, 2015
16:01 EDTVVUSVIVUS reports Q4 EPS (25c), consensus (25c)
Reports Q4 revenue $21.7M, consensus $20.01M.
10:06 EDTALKSHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
10:01 EDTNFLXNetflix teams up with Judd Apatow for 'Pee-wee's Big Holiday'
Netflix will premiere exclusively in all of its territories the new feature film, Pee-wee's Big Holiday, starring Paul Reubens as the beloved fun-loving hero of TV, stage and film, Pee-wee Herman. Judd Apatow and Reubens, who worked together to bring the project to fruition, will produce the film. Production is slated to begin in early 2015.
08:56 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTALKSAlkermes 7106 halt overshadows Q4 beat, says Credit Suisse
Subscribe for More Information
07:15 EDTNFLXNetflix may enter Russia within two years, Hollywood Reporter says
Netflix' head of communications in Europe, Joris Evers, says the company hopes to make its entrance in Russia within the next two years, The Hollywood Reporter says. Reference Link
07:06 EDTALKSAlkermes sees FY15 adjusted EPS 27c-40c, consensus 20c
Subscribe for More Information
07:03 EDTALKSAlkermes reports Q4 EPS 11c, consensus 4c
Subscribe for More Information
07:01 EDTALKSAlkermes announces phase 1 results for ALKS 7106, will not proceed to phase 2
Subscribe for More Information
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:01 EDTNFLXOptions Update; February 19, 2015
iPath S&P 500 VIX Short-Term Futures down 70c to 30.11. Option volume leaders: AAPL TSLA TWTR AMAT PBR KO FB AXP NFLX according to Track Data.
14:38 EDTTSNGovernment panel continues to recommend lean meat, Bloomberg says
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
February 18, 2015
16:00 EDTNFLXOptions Update; February 18, 2015
Subscribe for More Information
12:53 EDTADNCVertex raises stake in Audience to 7.3% from 5.1%
09:37 EDTNFLXOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use